Anti-CD6 (Itolizumab), Humanized Antibody

CATALOG NO.: A2164-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized recombinant IgG1 monoclonal antibody that specifically targets the scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. CD6 is a co-stimulatory molecule that is primarily expressed on the T-cell surface and plays an important role in the maturation, activation, and differentiation of T-cells, and pro-inflammatory cytokine production. Binding of the antibody to CD6 prevents T-cell activation, decreases the levels of IFN-γ, IL-6, and TNF-α and thus reduces inflammation. The original drug was approved by the DCGI in India to treat moderate-to-severe plaque psoriasis. In 2020, the drug received approval to treat moderate-to-severe COVID-19 complications.

ALTERNATE NAMES: T1h, XQQ2RHV14N, TP120, T12

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human CD6

CAS NUMBER: 1116433-11-4

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:
- Anti-IL-17α (Ixekizumab), Humanized Antibody (A2149)
- Anti-IL-6Ra (Sarilumab), Human IgG1 Antibody (A2133)
- Anti-IL-17α (Secukinumab), Human IgG1 Antibody (A2154)
- Anti-IL-17Ra (Brodalumab), Human IgG2 Antibody (A2155)
- Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)
- Anti-IL-1β (Canakinumab), Human IgG1 Antibody (A2144)

FOR RESEARCH USE ONLY! Not to be used on humans.